Premium
Integrated analysis identifying new lncRNA markers revealed in ceRNA network for tumor recurrence in papillary thyroid carcinoma and build of nomogram
Author(s) -
Chen Fangyao,
Li Zhe,
Deng Changyu,
Yan Hong
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.29273
Subject(s) - nomogram , competing endogenous rna , thyroid carcinoma , microrna , oncology , biomarker , papillary thyroid cancer , thyroid cancer , medicine , biology , cancer , long non coding rna , computational biology , bioinformatics , rna , gene , thyroid , genetics
Object The risk of tumor recurrence is currently the focus of clinical attention in the treatment of papillary thyroid carcinoma (PTC). This study focuses on the identification of novel prognostic long noncoding RNA (lncRNA) signatures for tumor recurrence in PTC. Method RNA sequencing profiling of patients with PTC was obtained from the TCGA and Gene Expression Omnibus databases. Differently expressed lncRNA, microRNA (miRNA), and messenger RNA (mRNA) signatures between patients with and without tumor recurrence were selected. The lncRNA‐miRNA‐mRNA competing endogenous RNA (ceRNA) network for tumor recurrence in PTC was constructed to identify lncRNAs associated with tumor relapse in papillary carcinoma. Functional enrichment analysis was performed. Adjusted odds ratios were estimated to identify candidate prognostic lncRNAs considering clinical covariates. Validation analysis was conducted. Nomogram was built based on the verified prognostic lncRNAs and clinical features. Results The lncRNA‐miRNA‐mRNA ceRNA network for tumor recurrence in PTC was constructed. Functional enrichment analysis suggested that the identified lncRNAs were associated with PTC. Adjusted odds ratios indicated that 5 of the 16 selected lncRNAs were candidate biomarkers predicting tumor recurrence of thyroid carcinoma. Among which, TTTY10 was verified as novel prognostic markers in validation analysis. Nomogram was built based on the newly identified lncRNA biomarker and clinical covariates. Conclusion In this study, lncRNA TTTY10 was identified as potential novel prognostic markers predicting tumor recurrence in PTC. It may provide useful information for future molecular and cohort studies focusing on the prognosis of PTC.